Revolutionizing Lung Cancer Therapy: A Surge of Targeted Drugs Transforms Treatment Landscape

　　【Pharmaceutical Network Product News】 Lung cancer has a relatively high incidence rate. With advancements in medical technology, multiple targeted drugs for lung cancer have been launched, bringing significant benefits to patients.
 

Recently, according to the approval progress inquiry on the China National Medical Products Administration (NMPA), the marketing authorization application submitted in China for Tecentriq (English name: Tecentriq; generic name: atezolizumab), a PD-L1 monoclonal antibody developed by Roche, has completed the review and approval process. This also means that Roche's PD-L1 monoclonal antibody will be officially approved, becoming a PD-L1 monoclonal antibody indicated for use in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer!
 

It is reported that Tecentriq is an innovative monoclonal antibody independently developed by Roche for tumor immunotherapy. Unlike tumor immunotherapies that specifically target PD-1, Tecentriq binds to the PD-L1 protein on the surface of both tumor cells and tumor-infiltrating immune cells. It not only blocks the binding of PD-L1 to the PD-1 receptor, but also prevents PD-L1 from binding to the B7.1 receptor, thereby helping the human immune system recognize tumor cells and further activating T cells to attack tumor cells.
 

Furthermore, in the field of lung cancer therapeutics, some Chinese enterprises have also achieved notable progress and are gradually advancing the overseas market expansion of their drugs. For instance, on October 21, the prominent biopharmaceutical company EQRx Group announced that it had signed a memorandum of understanding with NHS England (NHSE). Both parties agreed to establish a long-term strategic partnership to enable patients in England to access EQRx’s innovative, high-quality, and affordable oncology drugs as early as possible.
 

Sugemalimab is a potentially best-in-class PD-L1 antibody independently developed by CStone Pharmaceuticals. It is expected to become an immunotherapy agent covering the entire patient population with both Stage III and Stage IV non-small cell lung cancer (NSCLC). Currently, EQRx has secured the overseas rights to sugemalimab through a strategic partnership. The signing of this memorandum also marks a significant step for CStone Pharmaceuticals' independently developed products in entering overseas markets. In the view of many industry insiders, through its collaboration with EQRx, CStone's proprietary drug sugemalimab is leveraging the UK market as a strategic foothold to actively expand globally, serving as a benchmark for Chinese innovative pharmaceutical companies taking their products overseas.
 

The author also learned that in the field of lung cancer therapeutics, mobocertinib has attracted significant attention due to its notable efficacy. Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed during or following platinum-based chemotherapy. Mobocertinib is now available in China; however, it has not been included in the national medical insurance scheme, making it relatively expensive.
 

Today, empowered by new technologies, novel therapeutics for lung cancer are continuously emerging, delivering clinical benefits to patients. Data indicates that in 2015, only three targeted therapies for non-small cell lung cancer (NSCLC) were available in China, a number that increased to twenty by 2021. Over this six-year period, treatment paradigms in this field have undergone transformative changes.
 

Moreover, as China continues to deepen its medical insurance reforms, a large-scale basic medical security network has been established. A wide variety of innovative drugs have been included in the medical insurance catalog, featuring targeted therapies for cancers such as lung cancer, thereby ensuring that a growing number of Chinese patients have access to medical care and insurance coverage. For instance, at the end of last year, 《National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2020 Edition)》 was officially released. According to this catalog, over 50 anti-tumor drugs in the oncology field have been covered by medical insurance, among which 11 are therapeutic agents indicated for lung cancer patients. These include osimertinib, anlotinib, crizotinib, alectinib, ceritinib, erlotinib, almonertinib, bevacizumab, camrelizumab, recombinant human endostatin, and paclitaxel, further enhancing the accessibility of innovative medications.